|
gptkbp:instance_of
|
gptkb:legal_case
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:pembrolizumab
|
|
gptkbp:analysis
|
statistical methods
|
|
gptkbp:analyzes
|
gptkb:pembrolizumab
|
|
gptkbp:business_model
|
gptkb:board_game
|
|
gptkbp:class
|
immune checkpoint inhibitor
|
|
gptkbp:clinical_trial
|
gptkb:Clinical_Trials.gov
gptkb:KEYNOTE-001
gptkb:KEYNOTE-002
KEYNOTE-005
|
|
gptkbp:collaborations
|
various institutions
|
|
gptkbp:collection
|
clinical assessments
|
|
gptkbp:committee
|
gptkb:battle
|
|
gptkbp:criteria
|
previous anti-PD-1 therapy
unresectable stage III or IV melanoma
|
|
gptkbp:duration
|
up to 24 months
|
|
gptkbp:finale_date
|
overall survival
progression-free survival
|
|
gptkbp:followed_by
|
up to 5 years
|
|
gptkbp:future_plans
|
further research needed
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
KEYNOTE-006
|
|
gptkbp:impact
|
changed treatment guidelines
|
|
gptkbp:is_compared_to
|
gptkb:ipilimumab
|
|
gptkbp:is_studied_in
|
multicenter
|
|
gptkbp:is_tested_for
|
Phase 3
|
|
gptkbp:issue_number
|
NC T01866319
|
|
gptkbp:location
|
multiple countries
|
|
gptkbp:members
|
placebo
|
|
gptkbp:notable_work
|
pembrolizumab showed superior efficacy
|
|
gptkbp:outcome
|
assessed
improved survival rates
|
|
gptkbp:population
|
diverse population
|
|
gptkbp:primary_source
|
Dr. Jeffrey S. Weber
|
|
gptkbp:published_year
|
gptkb:2016
|
|
gptkbp:publishes
|
gptkb:New_England_Journal_of_Medicine
peer-reviewed
|
|
gptkbp:recorded_by
|
gptkb:battle
|
|
gptkbp:regulatory_compliance
|
FDA approved
|
|
gptkbp:result
|
gptkb:2016
|
|
gptkbp:safety_features
|
acceptable
|
|
gptkbp:side_effect
|
immune-related adverse events
improved in treatment group
|
|
gptkbp:sponsor
|
gptkb:Merck_&_Co.
|
|
gptkbp:status
|
completed
|
|
gptkbp:student_enrollment
|
approximately 690 patients
|
|
gptkbp:targets
|
gptkb:healthcare_organization
|
|
gptkbp:treatment
|
two
monotherapy
|
|
gptkbp:vision
|
double-blind
|
|
gptkbp:warranty
|
ongoing
|
|
gptkbp:year
|
gptkb:2015
|
|
gptkbp:year_created
|
gptkb:2013
|